Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

Part of paid clinical trials in Charlotte, North Carolina.

Sponsor
Wake Forest University Health Sciences
Study ID
NCT04174742
Status
Recruiting

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • pegfilgrastim — DRUG
    It works by increasing neutrophil migration to counteract cytotoxicity. It is commonly administered to patients receiving chemotherapy for breast cancer treatment. It has been shown to significantly reduce the incidence of neutropenic fever, although without statistically significant impact on overall survival.

Study Details

The overall purpose of this study is to investigate whether younger subjects report pain with pegfilgrastim (or biosimilar substitution) more often and/or at higher levels (greater intensity) than older subjects.This study will be carried out throughout the course of your chemotherapy treatment, which will be prescribed by your study doctor. Participation in this study will not affect your cancer treatment.

Key Dates

Start date
Dec 17, 2019
Status verified
May 2026
Primary completion
Jan 31, 2041
Completion
Jan 31, 2041

Study Design

Enrollment
115 participants (estimated)

Arms

  • Arm: A
    Subjects 45 years of age or younger
  • Arm: B
    Subjects over 45 years of age

Primary Outcome Measure

Frequency of pain [ Time Frame: approx 7 months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Levine Cancer InstituteCharlotteNorth Carolina28204
Laura Moore, RN
980-442-2340
Julie Fisher, MD (PRINCIPAL_INVESTIGATOR)
Wake Forest Baptist Comprehensive Cancer CenterWinston-SalemNorth Carolina27157
Marissa Howard-McNatt
336-716-9283
Marissa Howard-McNatt, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Charlotte, NC

By condition

Related Studies